ＡＬＫ２キナーゼのイミダゾール含有阻害剤

Japanese Patent JP7257338

B2

Disclosed are compounds of formula I, II, III, and IV, and pharmaceutically acceptable salts thereof. The compounds are inhibitors of ALK2 kinase. Also provided are pharmaceutical compositions comprising a compound of formula I, II, III, or IV, or pharmaceutically acceptable salt thereof, and methods involving use of the compounds or pharmaceutically acceptable salts thereof and compositions in the treatment and prevention of various diseases and conditions, such as fibrodysplasia ossificans progressiva.

Kotian, Pravin Er
Bab, Yararagadda Es
Kumar, Vee Satish
Zhang, Weiha
Ruh, Pong-Cheon
Raman, Krishnan

JP2019568599A

April 13, 2023

June 14, 2018

Click for automatic bibliography generation  

BIOCRYST PHARMACEUTICALS,INC.

C07D233/88; A61K31/4164; A61K31/4178; A61K31/4709; A61K31/4725; A61K31/517; A61K31/519; A61K31/53; A61P11/00; A61P25/00; A61P35/00; A61P43/00; C07D401/04; C07D401/12; C07D401/14; C07D403/12; C07D403/14; C07D405/12; C07D471/04; C07D487/04; C07D491/08; C07D495/04; C07D513/04

JP2013032343A
JP2004501914A
JP2016513661A
JP2012504157A
JP10095776A

Lim, Jongwon et al,Discovery of 1-(1H-Pyrazolo[4,3-c]pyridin-6-yl)urea Inhibitors of Extracellular Signal-Regulated Kinase (ERK) for the Treatment of Cancers,Journal of Medicinal Chemistry,2016年,59(13),,6501-6511
Database REGISTRY,2015年07月,RN 1797159-90-0, 1314071-05-0,Retrieved from STN international [online] ;retrieved on 6 May 2022

Hiroshi Higuchi

Previous Patent: Beverage preparation machine that recognizes capsules

Next Patent: BRAKING FORCE CONTROL DEVICE